Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
AssigneeCelldex Therapeutics, Inc.
InventorsLizhen HE, Tibor KELER, Anna WASIUK
Life of this patent
Estimating the term…
Abstract
Methods of performing adoptive immunotherapy comprising administering to patients a CD27 antibody in combination with an adoptive immunotherapy (e.g., genetically modified autogenous and allogenous T-cells) are provided.
Claims32
A method of conditioning treatment for adoptive cell therapy (ACT) in a subject in need thereof comprising:
- i) administering a CD27 antibody to the subject;
- and
- ii) transferring autogenic or allogenic T-cells to the subject.
A method of treating cancer in a subject in need thereof comprising the steps of:
- i) administering a CD27 antibody to the subject;
- and
- ii) transferring autogenic or allogenic T-cells to the subject,
- thereby treating cancer in the subject.
The method of any of the preceding claims wherein the CD27 antibody causes depletion of regulatory T-cells (Treg), CD4-Th and/or CD8 T-cells in the subject.
The method of any of the preceding claims wherein the CD27 antibody causes preferential depletion of regulatory T-cells (Treg) compared to CD8 cells in the subject.
The method of any of the preceding claims wherein the CD27 antibody causes blocking of ligand CD70 binding with CD27 receptor.
The method of any of the preceding claims wherein the transferred T-cells are genetically engineered T-cells.
The method of any of the preceding claims wherein the transferred T-cells are tumor infiltrating lymphocytes (TILs).
The method of any of the preceding claims wherein the transferred and expanded T-cells display an effector phenotype and function.
The method of any of the preceding claims wherein the transferred and expanded T-cells respond to antigen stimulation.
The method of any of the preceding claims wherein the transferred and expanded T-cells display antitumor activity.
The method of any of the preceding claims wherein the CD27 antibody is a depleting antibody.
The method of any of the preceding claims wherein the CD27 antibody is an IgG1 antibody.
The method of any of the preceding claims wherein the CD27 antibody is able to block CD70-CD27 interaction.
The method of any of the preceding claims wherein the CD27 antibody is administered at least 12 hours before the T-cells are transferred.
The method of any of the preceding claims wherein the T-cells are administered by intravenous infusion.
Use of a CD27 antibody as a conditioning agent in adoptive T-cell therapy (ACT).
A CD27 antibody for use as a conditioning agent in adoptive T-cell therapy (ACT). A CD27 antibody for use as a conditioning agent in adoptive T-cell therapy to replace or combine with Cy and Flu combo.
A genetically engineered T-cell which expresses a mutated human CD27 (hCD27) receptor such that the engineered T-cell is activated by recipient endogenous human CD70 but is significantly less depleted by an anti-hCD27 antibody than recipient T-cells.
Dependencies are inferred from the claim text.